Grizzi, Giulia
Grizzi, Giulia
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice
2016-01-01 Caccese, M; Ferrara, R; Pilotto, S; Carbognin, L; Grizzi, G; Caliò, A; Brunelli, M; Cuppone, F; Petraglia, S; Scarpa, A; Tortora, G; Bria, E
Do immune checkpoint inhibitors need new studies methodology?
2018-01-01 Ferrara, Roberto; Pilotto, Sara; Caccese, Mario; Grizzi, Giulia; Sperduti, Isabella; Giannarelli, Diana; Milella, Michele; Besse, Benjamin; Tortora, Giampaolo; Bria, Emilio
Multicentre match-paired analysis of advanced biliary cancer long-term survivors: The BILONG study
2022-01-01 Caputo, Francesco; Gelsomino, Fabio; Spallanzani, Andrea; Pettorelli, Elisa; Benatti, Stefania; Ghidini, Michele; Grizzi, Giulia; Ratti, Margherita; Merz, Valeria; Messina, Carlo; Tonelli, Roberto; Luppi, Gabriele; Melisi, Davide; Dominici, Massimo; Salati, Massimiliano
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies
2018-01-01 di Noia, Vincenzo; D'Argento, Ettore; Pilotto, Sara; Grizzi, Giulia; Caccese, Mario; Iacovelli, Roberto; Tortora, Giampaolo; Bria, Emilio
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations
2018-01-01 Pilotto, S; Grizzi, G; Sperduti, I; Simbolo, M; Vicentini, C; Caliò, A; Caccese, M; Mafficini, A; Carbognin, L; Corbo, V; Gkountakos, A; Santo, A; Infante, M; Brunelli, M; Scarpa, A; Tortora, G; Bria, E
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.
2017-01-01 Grizzi, Giulia; Caccese, M; Gkountakos, A; Carbognin, L; Tortora, G; Bria, E; Pilotto, S
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice | 1-gen-2016 | Caccese, M; Ferrara, R; Pilotto, S; Carbognin, L; Grizzi, G; Caliò, A; Brunelli, M; Cuppone, F; Petraglia, S; Scarpa, A; Tortora, G; Bria, E | |
| Do immune checkpoint inhibitors need new studies methodology? | 1-gen-2018 | Ferrara, Roberto; Pilotto, Sara; Caccese, Mario; Grizzi, Giulia; Sperduti, Isabella; Giannarelli, Diana; Milella, Michele; Besse, Benjamin; Tortora, Giampaolo; Bria, Emilio | |
| Multicentre match-paired analysis of advanced biliary cancer long-term survivors: The BILONG study | 1-gen-2022 | Caputo, Francesco; Gelsomino, Fabio; Spallanzani, Andrea; Pettorelli, Elisa; Benatti, Stefania; Ghidini, Michele; Grizzi, Giulia; Ratti, Margherita; Merz, Valeria; Messina, Carlo; Tonelli, Roberto; Luppi, Gabriele; Melisi, Davide; Dominici, Massimo; Salati, Massimiliano | |
| Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies | 1-gen-2018 | di Noia, Vincenzo; D'Argento, Ettore; Pilotto, Sara; Grizzi, Giulia; Caccese, Mario; Iacovelli, Roberto; Tortora, Giampaolo; Bria, Emilio | |
| Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations | 1-gen-2018 | Pilotto, S; Grizzi, G; Sperduti, I; Simbolo, M; Vicentini, C; Caliò, A; Caccese, M; Mafficini, A; Carbognin, L; Corbo, V; Gkountakos, A; Santo, A; Infante, M; Brunelli, M; Scarpa, A; Tortora, G; Bria, E | |
| Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. | 1-gen-2017 | Grizzi, Giulia; Caccese, M; Gkountakos, A; Carbognin, L; Tortora, G; Bria, E; Pilotto, S |